Opus Genetics Inc. Common Stock (IRD)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Opus Genetics is a clinical-stage biopharmaceutical company with 27 employees, developing gene therapies for inherited retinal diseases. That is not a conventional business; it is a collection of scientific bets. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, had revenue of $755,000 and net income of -$8.1 million. For FY2025 ended 2025-12-31, revenue was $14.2 million and net income was -$49.6 million. Revenue fell from $19.0 million in FY2023 to $11.0 million in FY2024, then rose to $14.2 million in FY2025, so growth is erratic, not durable. The company paid no dividend and generated trailing free cash flow of -$40.7 million, a -11.5% FCF yield. Financial health is weak: FairStock calculates a Piotroski score of 2/9 and an Altman Z-score of -1.43. Debt is low, with D/E of 0.07, but that matters little when losses consume cash. At the 2026-10-13 close of $4.24, market cap was $352.8 million; FairStock calculations show P/E -3.29 and P/B 21.82. ROE of -4796.52% and ROCE of -48.06% show capital is being consumed. On the positive side, beta of 0.58 suggests lower market sensitivity, and the pipeline can create option value if trials succeed. But I see no economic moat yet, no consistent profits, and no margin of safety from earnings. Graham would demand proof; Buffett would ask whether the science is understandable and the cash runway adequate. The FairStock score of 34/100 points to hope, not proven value. This is a speculation on clinical success.

In plain English: Opus Genetics is a small healthcare company that is trying to develop gene therapies to treat inherited eye diseases that can cause blindness. It is not making a profit, has very little revenue compared with its spending, and burns cash, so the business looks financially weak today. At its $4.24 close on 2026-10-13, the stock looks speculative and expensive compared with current sales and earnings rather than supported by steady profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer